Top life sciences deals of 2025 signal a bigger capital shift

CURRENT FULL VERSION: PharmaShots has published its “Top 20 Life Sciences Deals of 2025” report, in partnership with DealForma, offering a year-end snapshot of the biggest transactions in a market that regained momentum as 2025 progressed. While the ranking is centered on human life sciences rather than veterinary medicine, it highlights the scale of capital being deployed across healthcare innovation, and that matters for animal health leaders tracking spillover effects in funding, competition, and consolidation. (linkedin.com)

The broader backdrop was a stronger second half for dealmaking, but the story was not limited to M&A alone. Deloitte reported that by the end of November 2025, life sciences M&A had reached 193 transactions worth $220 billion, surpassing 2024’s total deal value. Its analysis also found average deal size rose sharply year over year, with companies leaning toward larger, more strategic, and more derisked assets. DealForma’s Q1 2025 review showed that even earlier in the year, R&D partnerships remained active, with 169 deals worth $60.4 billion in the first quarter alone. PharmaShots’ separate “Top 20 Healthcare IPOs of 2025” report adds another piece of the picture: investor appetite remained strong across biotech, medtech, digital health, and AI-enabled healthcare, with high-value raises led by Medline Industries at $7.2 billion, followed by Caris Life Sciences at $494 million and Lumexa Imaging at $462.5 million. The IPO ranking also pointed to a clear tilt toward AI-driven drug discovery, precision medicine, advanced diagnostics, and digital care platforms. (deloitte.com)

What PharmaShots adds is a curated, ranked view of which transactions defined the year. The article says the report was built with 2025 deals data from DealForma, and the visible portion of the ranking shows No. 20 as Tanabe Pharma’s business unit purchase deal with Shionogi & Co., dated December 22, 2025, valued at $2.5 billion. Even from that partial view, the framing is clear: 2025 was a year when scale mattered, and when deal activity stretched across business-unit sales, partnerships, and platform-building transactions. Other PharmaShots coverage from the year reinforces that theme. In one example, CVC Capital Partners proposed an approximately €10.9 billion acquisition of Recordati at €52 per share, seeking to buy the shares it did not already own and take the company private. Recordati is not a veterinary company, but the proposed transaction illustrates continued buyer interest in scaled specialty-pharma assets, including businesses with rare-disease exposure after Recordati’s earlier expansion through the EUSA Pharma acquisition. (linkedin.com)

For veterinary readers, the more important question is how much of that energy is likely to influence animal health. There are signs the connection is real, even if indirect. A Q4 2025 pet-sector M&A update based on PitchBook data found veterinary care services logged eight reported deals in the quarter, while pet and animal services remained one of the more active subsectors. The same report highlighted completed transactions involving veterinary and livestock-facing businesses, including Apiam Animal Health in Australia. Separately, a Q2 2025 pet M&A update tracked smaller but relevant transactions involving veterinary clinics, animal-health bacteriophage companies, pet transfusion systems, and companies serving both human and veterinary medicine. At the same time, the capital pool behind healthcare innovation continued to deepen. PharmaShots reported that Blackstone closed Blackstone Life Sciences VI at its $6.3 billion hard cap, making it roughly 40% larger than its predecessor fund. Blackstone said the platform had about $15 billion in assets under management as of Q4 2025 and had committed about $2 billion over the prior 12 months through partnerships with companies including Merck, Teva, Alnylam, and Novartis. That kind of fund size does not automatically translate into veterinary investment, but it does signal that sophisticated investors still have substantial appetite for drug, medtech, and royalty-backed healthcare opportunities. (rlhulett.com)

Industry advisers are also describing a more selective, strategy-driven market rather than a return to indiscriminate buying. In Capstone Partners’ March 2026 pet-sector update, Managing Director Tom Elliott said the market has shifted from the pandemic-era deal rush to a “more strategic, selective approach” in which profitable, high-quality assets still attract premium valuations. Capstone said 2026 activity has been concentrated in food, services, and vet-and-health segments, suggesting buyers still see durable demand in pet health and veterinary-adjacent businesses. That lines up with the broader healthcare financing picture from 2025, where both large IPOs and large private funds favored scaled platforms, revenue-generating businesses, and technology-enabled models over purely speculative growth stories. (capstonepartners.com)

Why it matters: Veterinary professionals may not feel the impact of a top-20 biopharma transaction immediately, but these deals can influence the operating environment in practical ways. Bigger life sciences deals can accelerate competition for diagnostics, specialty therapeutics, AI-enabled platforms, and manufacturing capacity. They can also reinforce investor interest in adjacent categories such as veterinary services, pet pharmacy, and animal health platforms. The IPO data adds another useful signal: capital in 2025 was not just chasing traditional drug developers, but also precision medicine, advanced diagnostics, digital health, and AI-enabled care models. Those are all areas with potential crossover into veterinary medicine, especially as clinics adopt more software, imaging, remote care, and specialty diagnostics tools. At the practice level, that can show up over time in vendor consolidation, referral-network changes, hiring competition, and shifting expectations from pet parents around access, convenience, and advanced care. AVMA’s 2025 economic report also shows how business structures in veterinary medicine have been evolving over time, with individual proprietorships declining and corporate forms representing a growing share of U.S. practice organization. (ebusiness.avma.org)

There’s also a financing angle. NVCA’s 2025 yearbook showed U.S. life sciences venture investment rose to $37.4 billion in 2024, up from $30.0 billion in 2023, underscoring that capital availability into health innovation had already improved before 2025’s larger M&A wave. Blackstone’s fund close and PharmaShots’ IPO roundup suggest that momentum carried forward in multiple forms: venture, public markets, and large private capital pools. That doesn’t guarantee more money for veterinary startups, but it supports the inference that animal health companies with strong margins, differentiated products, or scalable service models may remain attractive targets if broader healthcare deal confidence holds. (nvca.org)

What to watch: In 2026, the key question is whether blockbuster human-health dealmaking translates into more visible animal-health transactions, especially in veterinary services, diagnostics, pet pharmacy, and tech-enabled care. Watch not only acquisitions, but also whether investor preferences seen in 2025 healthcare IPOs, such as AI-enabled platforms, precision diagnostics, and revenue-generating care models, start showing up more clearly in veterinary funding and exit activity. KPMG’s 2026 healthcare and life sciences investment outlook found M&A appetite remained strong among investors, and pet-sector advisers are already reporting a rebound in delayed transactions. For veterinary teams, that means watching not just who buys whom, but where capital starts clustering next. (kpmg.com)